New studies on blood tests, biomarkers, and longevity — read and explained the week they break, with links to the actual research.
The FDA approved SimpleScreen CRC on July 27. It detects colorectal cancer from a blood draw with 81.1% sensitivity. It detects advanced precancerous lesions 13.7% of the time, and that second number is the one that decides what this test can replace.
On July 30 he posted one sentence and left it there. Weeks earlier he had disclosed a diagnosis of autoimmune gastritis, and he now says he is switching from handing out longevity advice to helping people find their own problems.
A Nature Aging study out of Amsterdam UMC and Maastricht University found that long-term exercisers were missing over half the molecular signature that defines aging muscle. The other half didn't move.
For decades, the only way to confirm endometriosis was surgery. Two blood tests reached US clinics in 2026 promising a diagnosis from a single draw. Neither has FDA clearance. Here is what that gap means.
A study published in Neurology linked high artificial-sweetener intake to a 62% faster decline in memory and thinking skills, but only in adults under 60. The age cutoff is the part most coverage skipped.
The FDA cleared a 92%-accurate blood test for Alzheimer's-linked amyloid over a year ago. The New York Times covered it this month. You still can't get it ordered on a routine physical. That's on purpose.